← All indications
Respiratory Syncytial Virus Infections
Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.
Drugs by status
Approved for this indication (7)
Phase 4 trials (5)
Phase 3 trials (20)
- Ziresovir
- diphtheria, tetanus and whole cell pertussis vaccine
- helium
- motavizumab
- palivizumab
- regn2222
- inactivated influenza vaccine
- mva-bn-rsv
- azithromycin
- oxygen
- rsv-f subunit vaccine
- sodium chloride
- phosphate
- varicella zoster virus glycoprotein e antigen
- RV521
- gsk3888550a
- interferon alpha-1
- 20-valent pneumococcal conjugate vaccine
- covid-19 mrna vaccine
- tnm001
Phase 2 trials (30)
- aln-rsv01
- aluminum
- alx-0171
- Enzaplatovir
- remdesivir
- Rilematovir
- lumicitabine
- peginterferon lambda-1a
- presatovir
- gsk3003891a
- rsv604
- rsv deltans2 delta1313 i1314l vaccine
- tarenflurbil
- edp-938
- rsv 276
- rsv 6120/∆ns2/1030s
- mv-012-968
- bars13
- Live-Attenuated Respiratory Syncytial Virus Vaccine
- alvr106
- mva-mbn294b
- vn-0200
- cpi-rsv-f
- edp-323
- rsvt vaccine
- rsv/hmpv vaccine
- lyb005
- in006
- s-337395
- a01b
Phase 1 trials (76)
- als-008112
- bacille calmette-guerin
- dabigatran
- bta9881
- cxcl1
- danirixin
- prednisone
- tacrolimus
- rosuvastatin
- rifampin
- carbamazepine
- medi-534
- medi-557
- medi7510
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- aluminum hydroxide
- caffeine
- quinidine
- rsv sf
- rv568
- cyclosporine
- desflurane
- syngem
- tivantinib
- fluconazole
- ttp889
- itraconazole
- verapamil
- as01
- d46/ns2/n/deltam2-2-hindiii
- +46 more
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (24)
- Gilead Sciences
- AstraZeneca
- Sanofi-Aventis
- Alnylam Pharmaceuticals
- Arrow Therapeutics
- Bavarian Nordic
- Enanta Pharmaceuticals
- Pulmocide Ltd
- University of London
- Gottfried Wilhelm Leibniz Universität Hannover
- University of Colorado, Denver
- hVIVO Services Limited
- Alios BioPharma
- Government of China
- Janssen Pharmaceutica NV
- University of Texas at Houston
- University of New South Wales
- Washington University in St. Louis
- University of Colorado
- Johnson and Johnson
- IQVIA
- ReViral Ltd
- Meissa Vaccines, Inc.
- CMAX Clinical Research
Organization Involved with Phase 1 Indications (21)
- Ablynx
- RespiVert
- MicroDose
- Aviragen Therapeutics
- ReiThera Srl
- Duke University
- Johns Hopkins University
- Pontificia Universidad Catolica de Chile
- Nucleus Network Ltd
- Quotient
- University of Queensland
- Pharmaceutical Research Associates, Inc. (PRA)
- Richmond Pharmacology
- University of Oxford
- Q-Pharm
- Johnson County Clin-Trials
- ICON
- Government of Chile
- Comisión Nacional de Investigación Científica y Tecnológica
- Millennium Institute on Immunology and Immunotherapy, Chile
- Codagenix, Inc
Organization Involved with Other Experimental Indications (5)